Profile data is unavailable for this security.
About the company
Vivoryon Therapeutics NV is a Germany-based clinical-stage biopharmaceutical company with focus on the research and development of new therapeutic products for the treatment of Alzheimer’s disease (AD) and other diseases with high medical need like Cancer and Fibrosis. The Company is developing a directed pipeline of product candidates with the project being a therapeutic approach for the treatment of AD. Its operations focus on the discovery and development of therapeutic programs, whereas operational research and development work is mainly outsourced to respective professional contract research organizations (CROs) or academic collaboration partners. Vivoryon strives to generate future revenues from licensing its product candidates to biopharmaceutical companies after development steps have been achieved or by commercializing products.
- Revenue in EUR (TTM)-3.62m
- Net income in EUR-28.34m
- Incorporated--
- Employees15.00
- LocationVivoryon Therapeutics NVWeinbergweg 22HALLE 06120GermanyDEU
- Phone+49 3 455559900
- Fax+49 3 455559901
- Websitehttps://www.vivoryon.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Poltreg SA | 205.47k | -3.57m | 48.98m | 23.00 | -- | 2.55 | -- | 238.35 | -3.36 | -3.36 | 0.193 | 18.07 | 0.0073 | 43.39 | 3.20 | 39,560.44 | -12.68 | -6.51 | -14.06 | -7.35 | -1,242.56 | -391.38 | -1,738.56 | -449.24 | 4.90 | -- | 0.0868 | -- | 40.04 | -- | -588.92 | -- | 214.26 | -- |
| GeNeuro SA | 0.00 | -14.76m | 52.08m | 19.00 | -- | -- | -- | -- | -0.594 | -0.594 | 0.00 | -0.5548 | 0.00 | -- | -- | 0.00 | -165.51 | -96.43 | -356.72 | -185.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -20.96 | -- | -20.13 | -- |
| Molecure SA | 82.23k | -5.00m | 53.81m | 112.00 | -- | 2.51 | -- | 654.41 | -1.35 | -1.35 | 0.0223 | 5.59 | 0.003 | -- | 0.0741 | 3,244.87 | -18.17 | 2.64 | -19.29 | 2.76 | -444.01 | 97.54 | -6,082.40 | 12.84 | -- | -- | 0.0657 | -- | -18.85 | 237.24 | -19.67 | -- | -24.82 | -- |
| Pangaea Oncology SA | 4.66m | -2.70m | 53.97m | 62.00 | -- | 2.65 | -- | 11.57 | -0.0898 | -0.0898 | 0.1557 | 0.6691 | 0.1601 | 3.86 | 1.23 | 76,449.51 | -9.46 | -11.40 | -10.90 | -14.62 | 38.92 | 79.42 | -59.10 | -57.87 | 2.57 | -- | 0.1054 | -- | -5.11 | 10.75 | -322.51 | -- | -33.46 | -- |
| Vivoryon Therapeutics NV | -3.62m | -28.34m | 56.56m | 15.00 | -- | 2.15 | -- | -- | -1.13 | -1.13 | -0.1434 | 1.01 | -0.1164 | -- | -- | -241,333.30 | -91.12 | -62.76 | -101.66 | -68.59 | -- | -- | -- | -1,308.60 | -- | -- | 0.0014 | -- | -- | -- | -0.6606 | -- | 100.16 | -- |
| AB Science SA | 970.00k | -11.99m | 57.28m | 53.00 | -- | -- | -- | 59.05 | -0.2492 | -0.2492 | 0.0195 | -0.4111 | 0.0393 | 0.9672 | 4.89 | 18,301.89 | -48.58 | -65.95 | -316.31 | -515.17 | 60.52 | 88.41 | -1,235.57 | -1,148.98 | 1.02 | -12.17 | -- | -- | 1.25 | -10.63 | 11.97 | -- | -6.55 | -- |
| Promimic AB | 3.51m | -833.76k | 57.72m | 17.00 | -- | 8.89 | -- | 16.42 | -0.5067 | -0.5067 | 2.14 | 3.91 | 0.4533 | -4.61 | 5.46 | 2,325,471.00 | -10.75 | -24.89 | -12.43 | -29.25 | 104.25 | 101.23 | -23.73 | -89.47 | 4.13 | -- | 0.00 | -- | 128.63 | -- | 41.95 | -- | -- | -- |
| Oncopeptides AB | 3.48m | -21.85m | 59.28m | 62.00 | -- | -- | -- | 17.03 | -1.93 | -1.93 | 0.3085 | -0.0664 | 0.1517 | -0.2669 | 0.8075 | 687,157.90 | -95.16 | -141.28 | -135.11 | -200.49 | 102.05 | -- | -627.53 | -2,689.06 | 2.33 | -- | 1.06 | -- | 321.54 | -- | 26.29 | -- | -- | -- |
| Gentian Diagnostics ASA | 12.45m | -510.65k | 59.41m | 58.00 | -- | 4.48 | 189.55 | 4.77 | -0.3783 | -0.3783 | 9.22 | 9.82 | 0.7646 | 1.85 | 6.35 | 2,452,035.00 | -3.14 | -10.76 | -3.58 | -11.86 | 50.84 | 41.46 | -4.10 | -26.99 | 4.14 | -- | 0.0555 | -- | 32.98 | 27.63 | 54.92 | -- | -4.92 | -- |
| BRAIN Biotech AG | 56.27m | -8.05m | 59.43m | 311.00 | -- | 3.23 | -- | 1.06 | -0.3683 | -0.3683 | 2.58 | 0.8424 | 0.7616 | 2.59 | 7.05 | 170,500.00 | -10.98 | -10.71 | -15.19 | -14.46 | 57.38 | 56.16 | -14.42 | -17.47 | 1.40 | -2.29 | 0.289 | -- | 11.79 | 14.12 | -25.63 | -- | 14.47 | -- |
| Venture Life Group PLC | 60.94m | 1.09m | 61.55m | 165.00 | 76.92 | 0.6802 | 6.42 | 1.01 | 0.0053 | 0.0053 | 0.3847 | 0.6028 | 0.42 | 2.80 | 3.15 | 311,575.80 | 0.7525 | 1.58 | 0.9274 | 1.83 | 39.19 | 40.14 | 1.79 | 3.99 | 0.7355 | 2.12 | 0.2424 | 0.00 | 16.89 | 22.33 | 77.12 | 31.30 | 18.85 | -- |
| Celadon Pharmaceuticals PLC | 88.90k | -8.46m | 61.57m | -- | -- | 16.06 | -- | 692.51 | -0.1154 | -0.1154 | 0.0012 | 0.0492 | 0.0067 | 136.80 | 0.0788 | -- | -64.63 | -- | -69.38 | -- | -7,196.00 | -- | -9,682.67 | -- | 2.55 | -10.78 | 0.5972 | -- | 212.50 | -- | 58.01 | -- | -- | -- |
| IRLAB Therapeutics AB | 504.75k | -13.98m | 62.61m | 28.00 | -- | 9.19 | -- | 124.04 | -3.03 | -3.03 | 0.1095 | 1.48 | 0.0274 | -- | 0.4652 | 218,384.60 | -75.97 | -27.12 | -94.23 | -30.42 | -1,952.47 | -72.18 | -2,770.38 | -155.57 | -- | -- | 0.2646 | -- | -90.71 | 216.07 | -56.82 | -- | -22.56 | -- |
| Intellego Technologies AB | 19.84m | 7.23m | 62.67m | 62.00 | 8.71 | 3.62 | 8.21 | 3.16 | 3.07 | 3.07 | 8.53 | 7.39 | 0.9087 | 5.24 | 2.82 | 3,600,549.00 | 33.13 | -- | 46.94 | -- | 68.45 | -- | 36.46 | -- | 2.13 | 7.89 | 0.1833 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
| Bioceltix SA | 0.00 | -3.48m | 63.26m | 30.00 | -- | 44.25 | -- | -- | -3.74 | -3.74 | 0.00 | 1.52 | 0.00 | 75.41 | -- | 0.00 | -217.09 | -- | -332.67 | -- | -- | -- | -- | -- | 2.51 | -- | 0.0154 | -- | -- | -- | -53.42 | -- | -- | -- |
Data as of Jun 18 2024. Currency figures normalised to Vivoryon Therapeutics NV's reporting currency: Euro EUR
19.98%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GS&P Kapitalanlagegesellschaft SAas of 30 Jun 2023 | 1.34m | 5.16% |
| Mackenzie Investments Europe Ltd.as of 31 Dec 2022 | 1.05m | 4.07% |
| Lupus alpha Asset Management AGas of 14 Feb 2024 | 769.50k | 2.97% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 472.00k | 1.82% |
| ETHENEA Independent Investors SAas of 30 Jun 2023 | 405.00k | 1.56% |
| Credit Suisse AGas of 31 Jan 2024 | 384.41k | 1.49% |
| Matejka & Partner Asset Management GmbHas of 29 Feb 2024 | 236.56k | 0.91% |
| UBS Asset Management (UK) Ltd.as of 30 Nov 2023 | 215.56k | 0.83% |
| Kairos Partners SGR SpAas of 29 Feb 2024 | 161.83k | 0.63% |
| LSP Advisory BVas of 31 Dec 2023 | 138.45k | 0.54% |
More ▼
Data from 30 Jun 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
